Biotech Values

[jq1234]

Of course, we won't know how much of the sales are in GTI in Q1 for awhile. Everyone had assumed that there were not enough GT2 and GT3 patients to produce the kind of sales that Sovaldi is doing, but we just won't know.

That's not accurate. GILD itself said majority patients were GT2 at JPM conference, but revised to say 70% were GT1 during earning call. If majority patients right now were GT2 as GILD said initially, I would bet GILD stock would be higher. 70% GT1 right now just takes away from future GT1 patients. That's my guess of what the market assumes at this point. Someone else might have done a survey and confirmed it.